Roche’s two new observational studies concluded that influenza patients treated with Tamiflu had significantly higher survival rates than untreated patients. The studies, examining nearly 1,000 people, analysed outcomes
Forest Laboratories (Forest) has presented new data from a complete analysis of FOCUS 1 and FOCUS 2, two global multicenter phase III studies of ceftaroline for the treatment
The FDA has accepted for review Merz Pharmaceuticals’ (Merz) premarket approval (PMA) application for Belotero Balance. Belotero Balance is a hyaluronic acid-based monophasic gel dermal filler that utilizes
Signum Biosciences has been awarded a $1.6m Small Business Innovation Research (SBIR) phase II grant by the National Institute of Allergy and Infection Diseases (NIAID), to continue the
New data from a study conduct by Eli Lilly showed that patients with chronic low back pain on Cymbalta (duloxetine HCl) has maintained reductions in pain for 41
Biocon and Amylin Pharmaceuticals (Amylin) have entered into an exclusive agreement to jointly develop, commercialise and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Reportedly,
Takeda and its wholly-owned subsidiary, Millennium Pharmaceuticals have initiated stage II of a phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer. TAK-700 is a
Theravance and Astellas have reported that the FDA has approved Vibativ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI). Vibativ is
Sanofi-aventis and Regeneron Pharmaceuticals have discontinued the phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine, for the first-line treatment of metastatic pancreatic
Genzyme has reported that a four-year follow-up data from its completed phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.